Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront

被引：0
|
作者：
Jimenez, J. Torres [1 ,2 ]
Gorria, T. [2 ]
Auclin, E. [3 ]
Castro, N. [4 ]
Albarran-Artahona, V. [2 ]
Ruffinelli, J. C. [5 ]
Pinato, D. [6 ]
Routy, B. [7 ]
Nana, F. Aboubakar
Reyes, R. [2 ]
Vinolas, N. [2 ,9 ]
Blanc-Durand, F. [8 ,10 ]
Lopes, G. [11 ]
Nadal, E. [12 ]
Arasanz, H. [4 ,13 ]
Pascal, M. [2 ,9 ]
Teixido, C. [2 ]
Besse, B. [10 ]
Reguart, N. [2 ,9 ]
Mezquita, L. [2 ,9 ]
Jimenez, J. Torres [1 ,2 ]
机构：
[1] Hosp Univ Ramon & Cajal, Madrid, Spain
[2] Hosp Clin Barcelona, Barcelona, Spain
[3] Univ Paris, Hop European George Pompidou, AP HP, Paris, France
[4] Hosp Univ Navarra, Pamplona, Spain
[5] Catalan Inst Oncol, Barcelona, Spain
[6] Hammersmith Hosp, Imperial Coll London, London, England
[7] Ctr Hosp Univ Montreal CHUM, Montreal, PQ, Canada
[8] Catholic Univ Louvain, Brussels, Belgium
[9] August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumor, Barcelona, Spain
[10] Gustave Roussy, Villejuif, France
[11] Univ Miami, Miami, FL USA
[12] Catalan Inst Oncol, Lhospitalet De Llobregat, Spain
[13] IdiSNA, Oncoimmunol Grp, Navarrabiomed, Pamplona, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
Gender; Immunotherapy alone; Immunotherapy combination with chemotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-09
引用
收藏
页码：S385 / S386
页数：2
相关论文
共 50 条
  • [1] Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone plus /- Chemotherapy Upfront
    Gorria, T.
    Torres-Jimenez, J.
    Auclin, E.
    Castro, N.
    Albarran-Artahona, V.
    Ruffinelli, J. C.
    Pinato, D.
    Routy, B.
    Nana, F. Aboubakar
    Reyes, R.
    Vinolas, N.
    Teixido, C.
    Blanc-Durand, F.
    Planchard, D.
    Lopes, G.
    Nadal, E.
    Arasanz, H.
    Pascal, M.
    Prat, A.
    Reguart, N.
    Besse, B.
    Mezquita, L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S386 - S386
  • [2] The efficacy of combination of chemotherapy and immunotherapy compared with immunotherapy alone for NSCLC
    Hirano, Satoshi
    Takahashi, Hidekazu
    Hiroyuki, Amano
    Toshiaki, Inazaki
    Kuroki, Tsuguko
    Urano, Akira
    Kure, Fujihiro
    Fujita, Tetsuo
    Nakamura, Makoto
    Nakamura, Sukeyuki
    ANNALS OF ONCOLOGY, 2022, 33 : S535 - S535
  • [3] Predictive and prognostic value of Patras Immunotherapy Score (PIOS) in patients with advanced NSCLC treated with immunotherapy/chemotherapy combination
    Dimitrakopoulos, F-I. D.
    Christopoulos, P.
    Elshiaty, M.
    Daniello, L.
    Pyrousis, I.
    Kottorou, A.
    Makatsoris, T.
    Kalofonos, C.
    Koutras, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1050 - S1050
  • [4] Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront.
    Blanc-Durand, F.
    Mielgo Rubio, X.
    Auclin, E.
    Ponce-Aix, S.
    Lopez Castro, R.
    Nadal, E.
    Planchard, D.
    Routy, B.
    Hendriks, L.
    Sullivan, I.
    Dempsey, N.
    Pilotto, S.
    Aboubakar, F.
    Pinato, D. J.
    Castonguay, M.
    Rodriguez, A.
    Amores, A.
    Bluthgen, M. V.
    Duchemann, B.
    Cruz Castellano, P.
    Aguado De La Rosa, C.
    Sereno Moyano, M.
    Ruffinelli, J.
    Lopez, G.
    Caramella, C.
    Besse, B.
    Mezquita, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S205 - S206
  • [5] Biomarkers for clinical outcome among patients with advanced or metastatic NSCLC treated with pembrolizumab alone or in combination with chemotherapy
    Abed, Afaf
    Beasley, Aaron
    Reid, Anna
    Law, Nc
    Leslie, Calapre
    Michael, Millward
    Johnny, Lo
    Elin, Gray
    RESPIROLOGY, 2023, 28 : 3 - 4
  • [6] Association of Baseline NLR and BMI with Clinical Outcomes in NSCLC Patients Treated with Immunotherapy Alone Versus Chemo-Immunotherapy
    Moudgalya, H.
    Basu, S.
    Bonomi, P.
    Fidler, M. J.
    Borgia, J. A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S354 - S354
  • [7] Immune-related adverse events in advanced NSCLC treated with immunotherapy alone or concurrent chemotherapy and immunotherapy.
    Melson, John
    Reed, Daniel
    Horton, Bethany J.
    Moore, Margaret
    Brown, Jacqueline Theresa
    Gentzler, Ryan D.
    Hall, Richard Delmar
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [8] Real-World Treatment Patterns and Outcomes in Patients With Advanced NSCLC Treated After Prior Chemotherapy and Immunotherapy
    Haggstrom, D.
    Mhatre, S. K.
    Chen, F.
    Gao, R.
    Carroll, C.
    Patel, R.
    Park, J.
    Descoteaux, A.
    Stokes, M.
    Daniel, D.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S409 - S409
  • [9] Association of Sarcopenia with Survival in Advanced NSCLC Patients Receiving Concurrent Immunotherapy and Chemotherapy
    Bolte, F. J.
    McTavish, S.
    Wakefield, N.
    Shantzer, L.
    Hubbard, C.
    Krishnaraj, A.
    Novicoff, W.
    Hall, R.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S353 - S353
  • [10] Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy
    Bolte, Fabian J. J.
    McTavish, Sloane
    Wakefield, Nathan
    Shantzer, Lindsey
    Hubbard, Caroline
    Krishnaraj, Arun
    Novicoff, Wendy
    Gentzler, Ryan D. D.
    Hall, Richard D. D.
    FRONTIERS IN ONCOLOGY, 2022, 12
12345